C62.91, Malignant neoplasm of right testis, unspecified whether descended or undescendedICD-10-CM
No Prior Auth Required
Code is covered without prior authorization (high confidence)
CGS-J15-L34356, Erythropoiesis Stimulating Agents (ESA)
J15
CGS-J15-L38067, MolDX: Next-Generation Sequencing for Solid Tumors
J15
CGS-J15-L38065, MolDX: Plasma-Based Genomic Profiling in Solid Tumors
J15
CGS-J15-L40225, MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer
J15
CGS-J15-L40386, Erythropoiesis Stimulating Agents (ESA)
J15
CGS-J15-L38822, MolDX: Minimal Residual Disease Testing for Cancer
J15
CGS-J18-L40225, MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer
J18
CGS-J18-L40386, Erythropoiesis Stimulating Agents (ESA)
J18
CGS-J18-L38822, MolDX: Minimal Residual Disease Testing for Cancer
J18
CGS-J18-L38067, MolDX: Next-Generation Sequencing for Solid Tumors
J18
CGS-J18-L38065, MolDX: Plasma-Based Genomic Profiling in Solid Tumors
J18
CGS-J18-L34356, Erythropoiesis Stimulating Agents (ESA)
J18
A57858, Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors
J5
A57936, Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors
J5
WPS-J5-L38158, MolDX: Next-Generation Sequencing for Solid Tumors
J5
WPS-J5-L38168, MolDX: Plasma-Based Genomic Profiling in Solid Tumors
J5
WPS-J5-L38835, MolDX: Minimal Residual Disease Testing for Cancer
J5
WPS-J5-L39040, MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer
J5
WPS-J5-L40277, MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer
J5
A58468, Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers
J5
Ask Backwork about documentation requirements, denial risks, or coverage in your state.